The Motley Fool: A Big Step Forward for Vertex Pharmaceuticals, Inc

There was no shortage of uncertainty and controversy around Vertex's (NASDAQ: VRTX  ) phase 3 trials for its cystic fibrosis (or CF) combo therapy. Bernstein analyst Geoffrey Porges was perhaps the most visible bear recently, asserting on June 16 that "the probability of failure in this trial is high". Now that Vertex has actually released the data, the bears are licking their wounds – the results of the TRAFFIC and TRANSPORT studies were not perfect, but a "B+" ought to be more than enough to get FDA approval, leading to upwards of $5 billion in incremental revenue.

Read more here:
A Big Step Forward for Vertex Pharmaceuticals, Inc

The Motley Fool: Vertex Pharmacueticals Inc Approaching a Huge Fork in the Road

Orphan drugs are hot these days, so when an investor finds a biotech focused on orphan drugs that appears to be undervalued, it certainly merits further investigation. In the case of Vertex (NASDAQ: VRTX  ) , it all comes down to risk and a major upcoming clinical data release -- If Phase III studies reveal success for a new combination therapy for cystic fibrosis, these shares could easily head to $100 (or higher). If the trials are declared failures, though, the downside could be $25 per share or higher.

Continue here for the full article:
Vertex Pharmacueticals Inc Approaching a Huge Fork in the Road